Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity.
暂无分享,去创建一个
[1] M. Gore,et al. Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Gore,et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A Gordon,et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] L. Grochow,et al. Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan. , 1997, Gynecologic oncology.
[5] R. Jelliffe. Letter: Creatinine clearance: bedside estimate. , 1973, Annals of internal medicine.
[6] E. Eisenhauer,et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Roger W. Jelliffe,et al. Creatinine Clearance: Bedside Estimate , 1973 .
[8] B. Sevin,et al. Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan. , 1998, Gynecologic oncology.
[9] L. Grochow,et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Boehm,et al. Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity , 1991 .
[11] M. H. Gault,et al. Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.
[12] H. Hansen,et al. Efficacy of low‐dose topotecan in second‐line treatment for patients with epithelial ovarian carcinoma , 2002, Cancer.
[13] T. Herzog,et al. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. , 2000, Gynecologic oncology.
[14] J. Rainey,et al. A Phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma , 2002, Cancer.
[15] Edmund E. Kim,et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Morgan,et al. Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial. , 1999, Gynecologic oncology.
[17] L. Grochow,et al. A phase II trial of topotecan in patients with previously untreated pancreatic cancer , 1996, Anti-cancer drugs.
[18] C. Drescher,et al. Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. , 2003, Gynecologic oncology.
[19] A. Munkarah,et al. Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer. , 2002, The oncologist.
[20] A. Lissoni,et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. von Pawel,et al. Preliminary Results of Combined Therapy with Topotecan and Carboplatin in Advanced Non-Small-Cell Lung Cancer , 2001, Oncology.
[22] D. M. Phillips,et al. Systemic treatment of cancer in the elderly. , 1988, Archives of gerontology and geriatrics.
[23] H. Kantarjian,et al. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. , 1999, Seminars in hematology.
[24] Armstrong,et al. Clinical Guidelines for Managing Topotecan-Related Hematologic Toxicity. , 1998, The oncologist.
[25] H. Hansen,et al. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] E. Swisher,et al. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. , 1997, Gynecologic oncology.
[27] J. Boehm,et al. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. , 1991, Journal of medicinal chemistry.
[28] M. Markman,et al. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. , 2000, Gynecologic oncology.
[29] L. Muderspach,et al. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. , 2001, Gynecologic oncology.
[30] C. Dunton,et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] F. Goldwasser,et al. Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients. , 1999, Anti-cancer drugs.
[32] L. Saltz,et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. , 1993, Journal of the National Cancer Institute.
[33] C. Hoppel,et al. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. , 2000, Gynecologic oncology.
[34] J. Carmichael,et al. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. , 1997, Seminars in oncology.
[35] L. Grochow,et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] S. Waggoner,et al. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study. , 2000, Gynecologic oncology.
[37] B. Karlan,et al. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. , 2000, Gynecologic oncology.
[38] S. Duffull,et al. Clinical Pharmacokinetics and Dose Optimisation of Carboplatin , 1997, Clinical pharmacokinetics.
[39] J. Fiorica,et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. , 2002, Gynecologic oncology.
[40] H. Kantarjian. New developments in the treatment of acute myeloid leukemia: focus on topotecan. , 1999, Seminars in hematology.
[41] J. Carmichael,et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] S. Engelholm,et al. Effect of topotecan on serum CA-125 in patients with advanced epithelial ovarian cancer. , 2000, Gynecologic oncology.
[43] L. Grochow,et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] F. Cabanillas. The role of topoisomerase-I inhibitors in the treatment of non-Hodgkin's lymphoma. , 1999, Seminars in hematology.
[45] L. Grochow,et al. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. , 1996, Journal of the National Cancer Institute.
[46] P. Rose,et al. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. , 2001, Gynecologic oncology.
[47] R. Bukowski,et al. Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine. , 1999, Seminars in oncology.
[48] H. Homesley,et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. , 2001, Gynecologic oncology.
[49] D Guthrie,et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.